Sanjaya K Satapathy1, Yun Ju Kim2, Ashish Kataria2, Arash Shifteh2, Rohan Bhansali3, Maurice A Cerulli1, David Bernstein1. 1. Division of Gastroenterology, NSLIJ Hofstra School of Medicine, Long Island Jewish Medical Center, 270-05 76th Avenue, New Hyde Park, NY 11040, USA ; Division of Gastroenterology, NSLIJ Hofstra School of Medicine, North Shore University Hospital, 225 Community Drive, Manhasset, NY, USA. 2. Department of Internal Medicine, NSLIJ Hofstra School of Medicine, Long Island Jewish Medical Center, 270-05 76th Avenue, New Hyde Park, NY 11040, USA. 3. Department of Cardiology, NSLIJ Hofstra School of Medicine, Long Island Jewish Medical Center, 270-05 76th Avenue, New Hyde Park, NY 11040, USA.
Abstract
BACKGROUND: An association of Coronary artery disease (CAD) with hepatitis C (HCV) has been suggested, but definitive data are still lacking. AIM: Our study sought to estimate the prevalence and severity of CAD in HCV patients compared to with age-, sex-, and race-matched controls without HCV infection. SUBJECTS AND METHODS: 63 HCV-infected patients were compared with 63 age, race, and sex-matched controls without HCV infection undergoing coronary angiography for evaluation of CAD. CAD was defined as more than a 50% blockage in any of the proximal coronary arteries on angiogram. The severity of the stenosis was defined by the modified Reardon severity scoring system: <50% stenosis of the luminal diameter, 1 point; 50-74%, 2 points; 75-99%, 3 points; 100% or total obstruction, 4 points. The points for each lesion in the proximal coronary circulation were summed to give the score for severity. RESULTS: A significantly higher prevalence of CAD was noted in the HCV population (69.8% vs. 47.6%, = 0.01). The combined Reardon's severity score in the HCV group was significantly higher compared to the controls (6.26 ± 5.39 vs. 2.6 ± 3.03, P < 0.0005). Additionally, significant multivessel CAD (>50% stenosis and ≥2 vessels involved) was also noted significantly more commonly in the HCV group compared to controls (57.1% vs. 15.9%, P < 0.0005). CONCLUSION: In this retrospective study the prevalence and severity of CAD was higher in HCV patients who were evaluated for CAD by angiogram compared with matched non-HCV patients. HCV-positive status is potentially a risk factor for CAD.
BACKGROUND: An association of Coronary artery disease (CAD) with hepatitis C (HCV) has been suggested, but definitive data are still lacking. AIM: Our study sought to estimate the prevalence and severity of CAD in HCV patients compared to with age-, sex-, and race-matched controls without HCV infection. SUBJECTS AND METHODS: 63 HCV-infectedpatients were compared with 63 age, race, and sex-matched controls without HCV infection undergoing coronary angiography for evaluation of CAD. CAD was defined as more than a 50% blockage in any of the proximal coronary arteries on angiogram. The severity of the stenosis was defined by the modified Reardon severity scoring system: <50% stenosis of the luminal diameter, 1 point; 50-74%, 2 points; 75-99%, 3 points; 100% or total obstruction, 4 points. The points for each lesion in the proximal coronary circulation were summed to give the score for severity. RESULTS: A significantly higher prevalence of CAD was noted in the HCV population (69.8% vs. 47.6%, = 0.01). The combined Reardon's severity score in the HCV group was significantly higher compared to the controls (6.26 ± 5.39 vs. 2.6 ± 3.03, P < 0.0005). Additionally, significant multivessel CAD (>50% stenosis and ≥2 vessels involved) was also noted significantly more commonly in the HCV group compared to controls (57.1% vs. 15.9%, P < 0.0005). CONCLUSION: In this retrospective study the prevalence and severity of CAD was higher in HCV patients who were evaluated for CAD by angiogram compared with matched non-HCV patients. HCV-positive status is potentially a risk factor for CAD.
Entities:
Keywords:
ACE, angiotensin converting enzyme; CAD, coronary artery disease; DM, diabetes mellitus; HCV, hepatitis C virus; HDL, high density lipoprotein; IR, insulin resistance; IVDU, intravenous drug use; LDL, low density lipoprotein; coronary artery disease; hepatitis C; prevalence
Authors: Henry Völzke; Christian Schwahn; Birger Wolff; Renate Mentel; Daniel M Robinson; Volker Kleine; Stephan B Felix; Ulrich John Journal: Atherosclerosis Date: 2004-05 Impact factor: 5.162
Authors: Adeel A Butt; Wang Xiaoqiang; Matthew Budoff; David Leaf; Lewis H Kuller; Amy C Justice Journal: Clin Infect Dis Date: 2009-07-15 Impact factor: 9.079
Authors: Sanjaya K Satapathy; Jason M Vanatta; Ryan A Helmick; Albert Flowers; Satish K Kedia; Yu Jiang; Bilal Ali; James Eason; Satheesh P Nair; Uzoma N Ibebuogu Journal: Transplantation Date: 2017-04 Impact factor: 4.939
Authors: Adeel A Butt; Peng Yan; Kara W Chew; Judith Currier; Kathleen Corey; Raymond T Chung; Ashfaq Shuaib; Abdul-Badi Abou-Samra; Javed Butler; Matthew S Freiberg Journal: Clin Infect Dis Date: 2017-08-15 Impact factor: 9.079
Authors: Juan Berenguer; Elena Rodríguez-Castellano; Ana Carrero; Miguel A Von Wichmann; Marta Montero; María J Galindo; Josep Mallolas; Manuel Crespo; María J Téllez; Carmen Quereda; José Sanz; Carlos Barros; Cristina Tural; Ignacio Santos; Federico Pulido; Josep M Guardiola; Rafael Rubio; Enrique Ortega; María L Montes; Juan J Jusdado; Gabriel Gaspar; Herminia Esteban; José M Bellón; Juan González-García Journal: Hepatology Date: 2017-06-22 Impact factor: 17.425
Authors: Simon H Bridge; Sabrina Pagano; Meleri Jones; Graham R Foster; Dermot Neely; Nicolas Vuilleumier; Margaret F Bassendine Journal: Hepatol Int Date: 2018-02-08 Impact factor: 6.047